You might also like
Becton, Dickinson and Company (BD) is a global medical technology company that develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products . The company operates through three principal business segments: BD Medical, BD Life Sciences, and BD Interventional . BD's products are marketed and sold worldwide, with operations organized into regions such as EMEA, Greater Asia, Latin America, and Canada .
-
BD Medical - Provides medication delivery solutions, medication management systems, pharmaceutical systems, and advanced patient monitoring products, serving hospitals, clinics, and other healthcare providers.
- Medication Delivery Solutions - Offers products like infusion pumps and syringes.
- Medication Management Solutions - Focuses on systems for managing medication.
- Pharmaceutical Systems - Develops systems for pharmaceutical applications.
- Advanced Patient Monitoring - Supplies monitoring solutions for patient care.
-
BD Life Sciences - Supplies products for specimen collection, diagnostic systems, and research tools, catering to hospitals, laboratories, and research institutions.
- Integrated Diagnostic Solutions - Provides comprehensive diagnostic solutions.
- Biosciences - Offers tools and systems for biological research.
-
BD Interventional - Delivers vascular, urology, oncology, and surgical specialty products, including surgery, peripheral intervention, and urology and critical care units.
- Surgery - Offers surgical specialty products.
- Peripheral Intervention - Provides solutions for vascular interventions.
- Urology and Critical Care - Supplies products for urology and critical care needs.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Christopher J. DelOrefice Executive | Executive Vice President and Chief Financial Officer | None | Christopher J. DelOrefice joined BDX in September 2021, previously holding senior financial roles at Johnson & Johnson. | |
David Shan Executive | Executive Vice President and Chief Integrated Supply Chain Officer | None | David Shan joined BDX in December 2017, progressing through senior roles in operations, quality, and supply chain. | |
Michael Feld Executive | Executive Vice President and President, Life Sciences Segment | None | Michael Feld joined BD in August 2024, previously serving as President of Hach at Veralto Corporation. | |
Michael Garrison Executive | Executive Vice President and President, Medical Segment | None | Michael Garrison has been with BDX for about 19 years, leading significant projects like the Alaris System clearance. | |
Michelle Quinn Executive | Executive Vice President and General Counsel | None | Michelle Quinn has elevated BD's legal, ethics, and compliance practices since joining in 2019. | |
Pamela L. Spikner Executive | Senior Vice President, Chief Accounting Officer, and Controller | None | Pamela Spikner joined BDX in January 2025, with over 25 years of expertise in corporate finance and accounting. | |
Pavan Mocherla Executive | Executive Vice President and President, Greater Asia | None | Pavan Mocherla has been with BDX since 2017, focusing on strategic innovation and regional management. | |
Richard Byrd Executive | Executive Vice President and President, Interventional Segment | None | Richard Byrd has been with BDX since 2016, recognized for strategic and operational excellence. | |
Roland Goette Executive | Executive Vice President and President, EMEA | None | Roland Goette has been with BDX since 2014, leading the EMEA region since 2017. | |
Shana Neal Executive | Executive Vice President and Chief People Officer | None | Shana Neal rejoined BDX in April 2022 after serving as Chief Human Resources Officer at Owens & Minor. | |
Thomas E. Polen Executive | Chairman, CEO, and President | None | Thomas E. Polen has been with BDX in various leadership roles, including CEO since January 2020, and Chairman since April 2021. | View Report → |
Bertram L. Scott Board | Director | Board member at Dollar Tree, Inc., Equitable Holdings, Inc., Lowe’s Companies, Inc. | Bertram L. Scott has been a director at BDX since 2002, with a background in healthcare and corporate governance. | |
Carrie L. Byington Board | Director | Professor at University of California, San Diego | Carrie L. Byington has been a director at BDX since 2021, with a background in healthcare leadership and academia. | |
Catherine M. Burzik Board | Director | Director at Haemonetics Corporation, Chair of the Board at Orthofix Medical Inc. | Catherine M. Burzik has been a director at BDX since 2013, with extensive experience in healthcare and medical devices. | |
Christopher Jones Board | Director | Chair of the Board of Trustees of The Pew Charitable Trusts | Christopher Jones has been a director at BDX since 2010, offering expertise in marketing, strategy, and management. | |
Claire M. Fraser Board | Director | Director at Seres Therapeutics, Inc. | Claire M. Fraser has been a director at BDX since 2006, with a strong background in genomics and molecular diagnostics. | |
Jeffrey W. Henderson Board | Director | Chairman of the Board at Halozyme Therapeutics, Inc., Director at Qualcomm, Inc. | Jeffrey W. Henderson has been a director at BDX since 2018, with deep knowledge of the healthcare industry and financial expertise. | |
Joanne Waldstreicher Board | Director | Director at Structure Therapeutics, Inc. | Joanne Waldstreicher joined the BDX Board in 2023, bringing over 30 years of experience in clinical and strategic leadership roles. | |
R. Andrew Eckert Board | Director | Senior Advisor to Permira, Lead Director at Fortrea Holdings Inc. | R. Andrew Eckert has been a director at BDX since 2016, with extensive leadership experience in healthcare technology. | |
Timothy M. Ring Board | Director | Lead Director at Quest Diagnostics Incorporated | Timothy M. Ring has been a director at BDX since 2017, with extensive experience in healthcare leadership from his time at C. R. Bard, Inc. | |
William M. Brown Board | Director | Lead Director at Celanese Corporation | William M. Brown has been a director at BDX since 2022, bringing strategic, financial, and operational expertise. |
-
You expect a mid-single-digit decrease in China revenues for fiscal year 2025 due to market dynamics ; can you elaborate on the specific challenges in China and the strategies you have in place to mitigate these headwinds?
-
Given the transitory dynamics affecting your bioscience pharma businesses, resulting in lower market demand for research instruments and reagents ; how do you plan to drive growth in this segment amid these challenges?
-
With strong growth in biologic drug delivery sales driven by GLP-1 demand, but noting expected customer inventory destocking impacting Pharma Systems ; what measures are you taking to address potential overreliance on specific therapies and ensure sustainable growth in the Pharma Systems segment?
-
You are increasing investments in AI and plan to launch AI-enabled devices across your platforms ; can you discuss how these investments will impact your top-line growth and operational efficiency, and what is the expected return on investment in the near term?
-
You announced a $1 billion share repurchase program while also focusing on capitalizing the value from the Advanced Patient Monitoring acquisition and managing net leverage ; how do you balance these capital allocation priorities, and does this indicate a temporary shift away from tuck-in acquisitions due to valuation concerns or integration capacity?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Edwards Lifesciences’ Critical Care product group | 2024 | BD acquired the Critical Care product group for $4.2 billion in cash, expanding its portfolio with smart connected care solutions that include advanced hemodynamic monitoring and AI-enabled decision tools; the deal, completed on September 3, 2024, also involved significant intangible assets and goodwill recognition expected to immediately boost revenue growth. |
Parata Systems | 2022 | BD acquired Parata Systems on July 18, 2022 for $1.548 billion in cash, integrating its pharmacy automation solutions into the Medication Management Solutions unit, which supports the BD2025 strategy and is expected to drive revenue growth through enhanced patient safety and operational efficiency; the acquisition also resulted in recognized goodwill and acquired technology and customer relationships. |
Cytognos | 2022 | BD acquired Cytognos in Q2 2022 to enhance its cancer discovery and monitoring capabilities, specifically using differentiated flow cytometry assays to detect minimal residual disease, as part of a broader $500 million capital commitment for strategic acquisitions within its Biosciences business; this move supports chronic disease management and BD2025 strategic initiatives. |
Tissuemed | 2022 | BD acquired Tissuemed in the first quarter of fiscal 2022 to bolster its biosurgery segment with an innovative surgical sealant applicable to a wide range of procedures, contributing to 17.5% revenue growth in the Surgery unit; the deal was part of $450 million cash outflows for strategic acquisitions aimed at strengthening BD’s durables portfolio. |
Venclose | 2022 | BD acquired Venclose in Q1 2022 as part of a tuck-in M&A strategy, paying cash as part of a $415 million total in early fiscal acquisitions to enter the treatment market for chronic venous insufficiency and to support the relaunch of the Venovo™ system in its Peripheral Intervention unit; the move is expected to drive growth in non-acute care CVI segments. |
Scanwell Health Inc. | 2022 | BD acquired Scanwell Health in Q1 2022 to extend its digital at-home testing capabilities, complementing its smart connected care strategy by providing a digital connected platform for point-of-care testing; although the financial details were not disclosed, the integration supports BD2025 initiatives for decentralized care and chronic disease outcome improvements. |
Recent press releases and 8-K filings for BDX.
- BD is advancing its long-term strategy to transform into a growth-oriented med tech company by exploring multiple separation options—including RMT, sale, or spin—to unlock shareholder value, with further details expected this summer.
- The management emphasized significant operational improvements driven by the BD Excellence initiative, noting a 370 basis point gross margin improvement in Q1 and targeted overinvestment in R&D and sales to drive future growth.
- The call highlighted key growth segments such as Medical Essentials, Connected Care, Biopharma Solutions, and Interventional, with a focus on new product launches and integrating AI platforms like the forthcoming standardized AI platform for BD systems.